Assertio

Search

Overview

Recent News

Date	Title and Summary
Toggle Summary Mar 16, 2020	Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million , Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd
Toggle Summary Mar 11, 2020	Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 LAKE FOREST, Ill. , March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50%
Toggle Summary Mar 09, 2020	Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results -- Reports Neurology Franchise Annual Net Sales of $108.1 Million , Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ® Totaling $502.5 Million -- -- Repaid in Full Senior Secured Debt and Reduced Convertible Debt by $188.0 Million --

Recent SEC Filings

Filing date	Description	Form	Filing Group	View
Aug 15, 2018	8-K12B	8-K12B	Other	View HTML 0001104659-18-052087.pdf 0001104659-18-052087.rtf 0001104659-18-052087.xls
Mar 29, 2002	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0000912057-02-012655.pdf 0000912057-02-012655.rtf 0000912057-02-012655.xls
Mar 25, 2015	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-15-002712.pdf 0001047469-15-002712.rtf 0001047469-15-002712.xls
Apr 05, 2016	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-16-011902.pdf 0001047469-16-011902.rtf 0001047469-16-011902.xls
Mar 16, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-18-001778.pdf 0001047469-18-001778.rtf 0001047469-18-001778.xls

IR Contact

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com

Independent Registered Public Accounting Firm

Ernst & Young LLP
Palo Alto, CA

Investor Relations Contact

investor@assertiotx.com